Sanofi has priced a €2 billion debt offering, with net proceeds to be used for general corporate purposes.
The French pharmaceutical giant is offering €850 million of zero percent fixed-rate notes due March 2022, €650 million of 0.875% fixed-rate notes due March 2029 and €500 million of 1.25% fixed-rate notes due March 2034.
Sanofi said the notes, being issued under a euro medium-term note program, will help the company lower its average cost of debt and extend the average maturity of the debt.
Bank of America Merrill Lynch and Natixis are serving as global coordinators and book runners. ING and Santander are also serving as book runners for the offering.